Arthritis News and Research

Latest Arthritis News and Research

Avoiding repetitive activities that increase stress on the joints may prevent bursitis

As warm weather arrives and the great outdoors beckons, more and more men and women will be taking to the trails, the beaches, or their yards and gardens, embarking on physical activities that may result in sore, aching, swollen joints.

8 Jun 2011

Study explores link between hospital procedure volume, surgical outcomes after joint replacements

Patients who undergo elective total hip or total knee arthroplasty at hospitals with lower surgical volume had a higher risk of venous thromboembolism and mortality following the procedure.

7 Jun 2011

Ligand's LGD-4033 Phase I clinical trial data presented at the Endocrine Society annual meeting

Ligand Pharmaceuticals Incorporated today announced that data from a comprehensive Phase I multi-dose program with its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation today at the Endocrine Society Annual Meeting in Boston, June 4-7, 2011.

7 Jun 2011

Bayer HealthCare seeks EU marketing authorization of VEGF Trap-Eye for treatment of wet AMD

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that Bayer HealthCare has submitted an application for marketing authorization in Europe for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD).

7 Jun 2011

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Bristol-Myers Squibb Company today announced results from a second Phase 3 randomized, double blind study demonstrating that YERVOY (ipilimumab) prolonged the lives of patients with metastatic melanoma.

6 Jun 2011

Ross River Fever vaccine trials begin

Australian researchers are working on a new vaccine that could protect against mosquito-borne Ross River Fever. They are conducting the world-first trial of the vaccine with positive results reported so far.

5 Jun 2011

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Bristol-Myers Squibb Company announced today it has entered in to a clinical collaboration agreement with Roche to evaluate the utility of Bristol-Myers Squibb's CTLA-4 inhibitor, YERVOY (ipilimumab), in combination with Roche's investigational oral BRAF inhibitor, vemurafenib, in treating patients with a specific type of metastatic melanoma.

4 Jun 2011

New approach for identifying 'self' proteins targeted in autoimmune diseases

Researchers from Harvard Medical School and MIT have developed a new approach for identifying the "self" proteins targeted in autoimmune diseases such as multiple sclerosis, diabetes and rheumatoid arthritis.

3 Jun 2011

McMaster, Abbott create new education chair to focus on rheumatology

Abbott, a global, broad-based health care company, and the Michael G. DeGroote School of Medicine at McMaster University today announced the creation of an endowed chair to focus on teaching the next generation of rheumatologists for the growing number of Canadians living with arthritis.

1 Jun 2011

Researchers discover new drug target that may effectively prevent onset of Huntington's disease

McMaster University researchers have discovered a new drug target that may be effective at preventing the onset of Huntington's disease, working much the same way heart medications slow the progression of heart disease and reduce heart attacks.

1 Jun 2011

SQI Diagnostics reports net loss of $1,874,000 for second quarter 2011

SQI Diagnostics Inc., a life sciences company that develops and commercializes proprietary multiplexing technologies and products for advanced microarray diagnostics, today announced its financial and operational results for the second quarter ended March 31, 2011.

30 May 2011

HHS uses new devices to meet growing need of joint replacements among baby boomers

"The number of patients in their 50s coming into my office asking for joint replacement is higher than ever," says Dr. Steven B. Haas, a knee surgeon at Hospital for Special Surgery in New York City.

30 May 2011

Positive data from Augurex's RA biomarker blood test, novel drug target presented at EULAR conference

Augurex Life Sciences Corp. today reported that in London at the European League Against Rheumatism Conference, leading arthritis researchers presented important data on Augurex's rheumatoid arthritis biomarker blood test and novel drug target.

30 May 2011

New positive Cimzia phase IIIb study data on rheumatoid arthritis presented at EULAR meeting

UCB today announced data which showed that the addition of Cimzia to current therapy was associated with a rapid and consistent clinical response in a diverse group of rheumatoid arthritis (RA) patients.

30 May 2011

Study: Cardiovascular disease may be under treated in rheumatoid arthritis patients

Results of a study, involving 98,454 patients demonstrated that at 30 days following their first heart attack, RA patients were approximately 20% less likely to be prescribed standard MI treatments, such as statins and betablockers, compared to healthy patients.

27 May 2011

Adalimumab plus methotrexate helps achieve higher levels of disease control in early RA

Data presented today at the EULAR 2011 Annual Congress demonstrated that initial treatment with adalimumab (Humira, ADA) plus methotrexate in early RA patients can provide high levels of disease control in many patients, and may also offer the opportunity to change future treatment options for some.

27 May 2011

4SC to present pre-clinical data on vidofludimus in systemic lupus erythematosus at EULAR 2011

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune and cancer diseases, will present pre-clinical data on vidofludimus - its lead small-molecule drug candidate against autoimmune diseases - in systemic lupus erythematosus at EULAR 2011, Europe's largest scientific conference on rheumatic diseases, in London, UK, from May 25-28, 2011.

27 May 2011

Positive results from CEL-SCI's LEAPS H1N1-activated dendritic cells trial in mice

CEL-SCI Corporation today announced the positive results of efficacy studies in mice of L.E.A.P.S.TM H1N1 activated dendritic cells to treat the H1N1 virus.

27 May 2011

Gout drug success for Novartis

Novartis AG's new gout therapy drug gives patients better pain relief and significantly cuts the risk of new attacks say two late stage studies. The studies show that more than 450 patients taking Ilaris, or ACZ885, had less pain and the risk of new attacks were reduced by up to 68 percent compared to those taking an injectable steroid to treat gouty arthritis attacks, which can last for a week or more.

26 May 2011

Specific influenza immunization strategies for RA patients may be required for future flu pandemics

A Brazilian hospital-based study assessed responses to flu vaccines in 340 RA patients in regular follow-up compared to 234 healthy patients.

26 May 2011

Arthritis News and Research

Latest Arthritis News and Research

Avoiding repetitive activities that increase stress on the joints may prevent bursitis

Study explores link between hospital procedure volume, surgical outcomes after joint replacements

Ligand's LGD-4033 Phase I clinical trial data presented at the Endocrine Society annual meeting

Bayer HealthCare seeks EU marketing authorization of VEGF Trap-Eye for treatment of wet AMD

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Ross River Fever vaccine trials begin

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

New approach for identifying 'self' proteins targeted in autoimmune diseases

McMaster, Abbott create new education chair to focus on rheumatology

Researchers discover new drug target that may effectively prevent onset of Huntington's disease

SQI Diagnostics reports net loss of $1,874,000 for second quarter 2011

HHS uses new devices to meet growing need of joint replacements among baby boomers

Positive data from Augurex's RA biomarker blood test, novel drug target presented at EULAR conference

New positive Cimzia phase IIIb study data on rheumatoid arthritis presented at EULAR meeting

Study: Cardiovascular disease may be under treated in rheumatoid arthritis patients

Adalimumab plus methotrexate helps achieve higher levels of disease control in early RA

4SC to present pre-clinical data on vidofludimus in systemic lupus erythematosus at EULAR 2011

Positive results from CEL-SCI's LEAPS H1N1-activated dendritic cells trial in mice

Gout drug success for Novartis

Specific influenza immunization strategies for RA patients may be required for future flu pandemics

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Arthritis News and Research

Latest Arthritis News and Research

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Newsletters you may be interested in